Profile data is unavailable for this security.
About the company
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
- Revenue in USD (TTM)500.00k
- Net income in USD-44.84m
- Incorporated2016
- Employees23.00
- LocationARS Pharmaceuticals Inc11682 El Camino Real, Suite 120SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 771-9307
- Fax+1 (845) 818-3588
- Websitehttps://ars-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics Inc | 132.06m | -198.76m | 1.22bn | 296.00 | -- | 6.50 | -- | 9.21 | -2.18 | -2.18 | 1.36 | 1.60 | 0.3451 | 0.8334 | 4.36 | 446,155.40 | -51.93 | -65.64 | -58.68 | -71.72 | 92.32 | -- | -150.51 | -1,513.03 | 8.19 | -5.94 | 0.5223 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Tyra Biosciences Inc | 0.00 | -80.88m | 1.23bn | 49.00 | -- | 3.25 | -- | -- | -1.69 | -1.69 | 0.00 | 7.13 | 0.00 | -- | -- | 0.00 | -25.18 | -- | -25.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Relay Therapeutics Inc | 35.21m | -322.83m | 1.23bn | 304.00 | -- | 1.48 | -- | 34.85 | -2.52 | -2.52 | 0.277 | 5.11 | 0.0406 | -- | -- | 109,003.10 | -37.22 | -28.55 | -39.91 | -29.54 | -- | -- | -916.92 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Gyre Therapeutics Inc | 165.85m | -79.66m | 1.30bn | 593.00 | -- | 19.66 | -- | 7.81 | -0.8638 | -0.8638 | 1.43 | 0.7056 | 2.49 | -- | 17.81 | 279,674.50 | -103.20 | -73.59 | -167.87 | -99.94 | 96.15 | -- | -41.48 | -205.62 | 3.07 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| ARS Pharmaceuticals Inc | 500.00k | -44.84m | 1.36bn | 23.00 | -- | 6.33 | -- | 2,724.06 | -0.466 | -0.466 | 0.0052 | 2.22 | 0.0021 | -- | -- | 20,833.33 | -18.66 | -20.37 | -19.33 | -21.32 | -- | -- | -8,968.40 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Ardelyx Inc | 210.00m | -65.15m | 1.39bn | 267.00 | -- | 9.45 | -- | 6.61 | -0.2788 | -0.2788 | 0.9052 | 0.6244 | 0.7572 | 2.74 | 9.06 | 786,513.10 | -23.49 | -46.14 | -30.26 | -57.32 | 86.03 | 88.15 | -31.02 | -240.87 | 3.99 | -6.91 | 0.4055 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Disc Medicine Inc | 0.00 | -91.00m | 1.42bn | 74.00 | -- | 2.90 | -- | -- | -3.66 | -3.66 | 0.00 | 16.45 | 0.00 | -- | -- | 0.00 | -20.35 | -- | -21.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| Cassava Sciences Inc | 0.00 | -15.37m | 1.45bn | 29.00 | -- | 7.70 | -- | -- | -0.4054 | -0.4054 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -6.97 | -30.74 | -8.35 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Xencor Inc | 133.62m | -177.37m | 1.46bn | 280.00 | -- | 2.28 | -- | 10.90 | -2.90 | -2.90 | 2.19 | 9.14 | 0.1666 | -- | 6.35 | 477,207.20 | -22.40 | -3.70 | -24.25 | -4.12 | -- | -- | -134.45 | -15.92 | -- | -- | 0.0331 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Dynavax Technologies Corp | 249.70m | 17.18m | 1.47bn | 408.00 | 110.87 | 2.28 | 67.81 | 5.88 | 0.1011 | 0.1011 | 1.76 | 4.91 | 0.2557 | 0.7766 | 4.76 | 611,997.60 | 1.76 | 4.16 | 1.86 | 5.71 | 82.03 | 64.83 | 6.88 | 9.19 | 13.18 | -- | 0.2578 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Spyre Therapeutics Inc | 0.00 | -185.98m | 1.47bn | 50.00 | -- | 6.73 | -- | -- | -15.42 | -15.42 | 0.00 | 7.37 | 0.00 | -- | -- | 0.00 | -54.73 | -101.87 | -87.47 | -118.83 | -- | -- | -- | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Belite Bio Inc (ADR) | 0.00 | -35.29m | 1.48bn | 20.00 | -- | 12.91 | -- | -- | -1.23 | -1.23 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -39.40 | -- | -39.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Arcus Biosciences Inc | 247.00m | -249.00m | 1.51bn | 577.00 | -- | 2.37 | -- | 6.10 | -3.10 | -3.10 | 3.02 | 6.96 | 0.2053 | -- | 7.06 | 428,076.30 | -20.70 | -15.85 | -24.57 | -18.25 | -- | -- | -100.81 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
Data as of Sep 19 2024. Currency figures normalised to ARS Pharmaceuticals Inc's reporting currency: US Dollar USD
29.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Jun 2024 | 10.86m | 11.20% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.64m | 3.76% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 3.12m | 3.22% |
| Franklin Advisers, Inc.as of 30 Jun 2024 | 2.95m | 3.04% |
| K2 & Associates Investment Management, Inc.as of 30 Jun 2024 | 2.46m | 2.54% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 1.86m | 1.92% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.20m | 1.23% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 1.09m | 1.12% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 867.32k | 0.90% |
| Royce & Associates LPas of 30 Jun 2024 | 645.70k | 0.67% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
